Drug Profile
Research programme: polyclonal immunoglobulins - Fabentech
Alternative Names: F(ab')2Latest Information Update: 21 Sep 2021
Price :
$50
*
At a glance
- Originator Fabentech
- Class Antibodies; Immunoglobulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crimean-Congo haemorrhagic fever virus infections; Ebola virus infections; Lassa fever; Nipah virus infections; Severe acute respiratory syndrome; Substance-related disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Crimean-Congo-haemorrhagic-fever-virus-infections in France (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Ebola-virus-infections in France (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Lassa-fever in France (Parenteral)